“The moral test of a government is how it treats those who are at the dawn of life, the children; those who are in the twilight of life, the aged; and those who are in the shadow of life, the sick and the needy, and the handicapped.” – Hubert Humphrey
passionate pachyderms
Pharmacist Steve steve@steveariens.com 502.938.2414
seems like the “street drug dealers” and the drug cartels … are bringing out more “new drugs” that the brand name pharmas do.. but.. then I suspect that the street dealers and the cartels are doing any clinical trials about safety and appropriate dosing 🙁 This new “street drug” may spread faster than the first version of COVID-19
‘Tranq Dope’ is a powerful new, potentially deadly drug raising alarms locally
A new drug called “Tranq Dope” is raising alarms in the Miami Valley because it is a combination of opioids and a drug used to sedate animals.
“We don’t expect it to be too long before it comes right up I-75 into the Miami Valley,” Charles Patterson, health commissioner, Clark County Combined Health District, told News Center 7′s Kayla McDermott on Friday.
There have already been 18 deaths from opioid use in Clark County this year, and Patterson said he fears the count will increase with a new drug entering the market.
Xylazine is the main drug used in Tranq Dope, most commonly found in veterinarian’s offices as a tranquilizer for animals.
“It’s a sedative, a muscle relaxer for animals, such as cattle,” Wendy Doolittle, CEO at McKinley Hall Inc. addiction center in Springfield. “So, it’s not approved for any human consumption.”
Patterson said the Xylazine has been watered down and spread as a similar to heroin type of drug.
When mixed with either opioids or fentanyl, the combination can be lethal.
Doolittle issued an ominous announcement: “I think we are about to see our death rate increase as a result of this being on the streets.”
In Hamilton County, the coroner’s office reports that 15 overdose victims that have tested positive for Xylazine in their systems.
Patterson said the Hamilton County Coroner’s Office has registered those deaths and has been able to perform screens for toxins in the blood.
Narcan won’t reverse the effects, Doolittle said, and those who survive using the drug are left with skin that starts to turn black at the injection site and then the skin starts to deteriorate, to break down. And it literally looks like just black decayed skin that continues to just kind of grow and peel could result in amputations.
Tranq Dope is so new the Ohio Department of Health still has several questions they want answered, such as whether the drug is the same from state to state in terms of composition and how much tranquilizer is in each dose.
“IF EVER ONE THINKS THEY’RE TOO SMALL TO MAKE CHANGES, THEN THEY HAVE NEVER SLEPT IN A TENT WITH A MOSQUITO !!!”
REPORTEDBY
NORMAN J CLEMENT RPH., DDS, NORMAN L.CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC.T. SPIRIT OF REV. C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., WALTER F. WRENN III., MD., JULIE KILLINGWORTH, LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., LEROY BAYLOR, JAY K. JOSHI MD., MBA, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
“WE ARE NOT POWERLESS, AND THROUGH OUR VIDEOS, WRITINGS, AND PHOTOGRAPHS WE WILL EXPOSE THE ABUSES AND TYRANNY JUST AS THE VIDEO WAS RECORDED BY THE CELL PHONE CAMERA OF YOUNG DARNELLA FRAZIER, BORE WITNESS TO THE MURDER OF GEORGE FLOYD THE BLOG youarewithinthenorms.com BARES WITNESS AND BOTH ALLOWS THE SYSTEM TO BE HELD ACCOUNTABLE”
UNITED STATES MOTION DISMISSED INDICTMENT BASED ON 9-0 SUPREME COURT RULING IN RUAN-KHAN
DONALD HYUNGJOON KIM, MD.
UNITED STATES’ MOTION TO DISMISS INDICTMENT
The United States of America, pursuant to Federal Rule of Criminal Procedure Rule 48(a), respectfully moves this Court to dismiss the Indictment, returned June 17, 2020, in the above-styled case without prejudice. Such action would best meet the ends of justice for the following reasons:
(OBJECTIVE STANDARDS)
1. On June 17, 2020, a federal grand jury issued an Indictment charging Defendant Donald Hyungjoon Kim, M.D. with 154 counts of distributing controlled substances outside the usual course of medical practice and without medical necessity to include 3 counts of distribution with death resulting. (Doc. 1.)
MUST PROVE BEYOND THE REASONABLE DOUBT
2. On June 27, 2022, the Supreme Court issued its opinion in Ruan v. United States, — U.S. —-, 142 S.Ct. 2370 (2022). In Ruan, the Supreme Court held that the government must “prov[e] that a defendant knew or intended that his or her conduct was unauthorized,” which inserted a mens rea requirement that had not previously been recognized. Id. at 2382; see United States v. Khan, 989 F.3d 806, 825 (10th Cir. 2021),
Case 5:20-cr-00163-PRW Document 53 Filed 07/29/22 Page 2 of 3
vacated and remanded by Ruan, 142 S.Ct. 2370 (holding that “§841(a)(1) and § 1306.04(a) require the government to provide that a practitioner-defendant either: (1) subjectively knew a prescription was issued not for a legitimate medical purpose; or (2) issued a prescription that was objectively not in the usual course of professional practice”).
INDICTMENT WAS DEFECTIVE
3. Based on this intervening Supreme Court ruling, the United States has concluded that the Indictment is defective. As such, the government believes that the ends of justice would best be served by dismissing, without prejudice, the Indictment in this case.
WHEREFORE, the United States requests that this Court enter an Order dismissing, without prejudice, the Indictment filed herein on June 17, 2020.
Respectfully submitted,
ROBERT J. TROESTER United States Attorney
Harvey Silverglate
Mr. Silverglate, a Boston criminal-defense and civil-liberties litigator, is the author of “Three Felonies a Day: How the Feds Target the Innocent” (Encounter, second edition 2011).
June 12, 2015, 6:42 pm ET
WHEN TREATING PAIN BRINGS A CRIMINAL INDICTMENT
” Federal drug-enforcement officials have made it a serious felony for doctors to overprescribe painkillers or, as the applicable law states, to prescribe controlled substances “other than for a legitimate medical purpose and in the usual course of professional practice.”
But the line between legitimate and illegitimate prescription—as drawn by the Drug Enforcement Administration (DEA) and the Justice Department—is far from clear. This puts physicians in great legal jeopardy and too often leaves their patients to suffer needless agony.
The Hidden mantra of the DOJ and DEA
“The atmosphere around prescribing for chronic pain had become so fraught that physicians felt they must avoid opioid analgesics even in cases when it contradicted their view of what would provide the best care for their patients.
In some cases, this desire to reduce opioid prescribing translated to doctors tapering patients off their medications without patient consent. In other words, it meant that physicians would no longer accept patients who had a history of needing high-dose opioids.”
CONSTITUTIONAL CULTURAL ART GALLERY JOHANNESBURG, SOUTH AFRICA
THE STRUGGLE
THE RULE OF LAW
The Rule of law is the most fundamental concept of our country without it our society crumbles which then allows for an agency to take anything they want unchecked based on their own manufactured rules and misinterpretation of laws, medical procedures guidelines. Thus creating their own science and facts.
In healthcare the great fear at the moment is the DEA operates unchecked as a rogue sub agency of government operating outside the rule of law creating their medical science.
ANALYSIS
Ruan provides: “ A strong scienter requirement helps reduce the risk of “over-deterrence,” i.e., punishing conduct that lies close to, but on the permissible side of, the criminal line.” An objective standard of care was not proven. The indictment used the improper evidentiary standard.”
THE JOURNEY
“AND IT SHALL BE CALLED YOUAREWITHINTHENORMS”
“AND IT SHALL BE CALLED YOUAREWITHINTHENORMS”
FOR NOW, YOU ARE WITHIN
YOUAREWITHINTHENORMS.COM,(WYNTON MARSALIS CONCERTO FOR TRUMPET AND 2 OBOES, 1984)
If this is representative of the USA’S potential future ?… for some reason… makes me not unhappy for being near the end of my life expectancy. Is it just me, but is this another female from New York city and looks/sounds like AOC ?
Because of the 2020 Census – 7 states gained House members and 7 states lost House members.. A member of the House represents about 700,000 constituents in their state. So during the 2010-2020 period abt FIVE MILLION of our citizens shifted the states they live in and from the graphic below – TEXAS was the biggest winner. California – for the first time EVER – lost a seat in the House, because of MORE PEOPLE MOVING OUT THAN MOVING IN.
I have a concern that “socialism” will lead to some sort of universal health insurance and if we follow Canada’s lead … here is a recent article about the state of Canada’s healthcare systemEuthanasia Is Now A Leading Cause Of Death In Canada, And Ethicists Are Freaking Out and guess who may be first on THE LIST, the high acuity – sickest of the sick and the ones that are consuming the most healthcare $$$ ?
I went thru the archives on my blog and found this blog post can’t always judge a book by its cover ? and here is a hyperlink within this post that I believe is also interesting reading from my blog’s archives.
I have expressed my confusion to Barb about all this destructive/disruptive behavior… she had a simple answer “…you were never a girl in Jr-Sr High School..” so the community is having to deal with some people using the social skills they used during puberty and they either never grew up when they left high school and/or they have DUG THEM UP and reconstituted those skill sets…. when they became – so called – pain advocates.
Only those in the community can “sanitize ” the community of these destructive malcontents. I am sure that those – on the outside – are paying attention to what is going on… and see this as further justifications for reducing opiate Rxs and lowing opiate production quotas even more… We know that the war on drugs focuses on maybe the 2% of chronic pain pts that will become addicted and the over whelming of the opiate OD/poisoning is from illegal fentanyl but “they” keep stating that all addicts started with a Rx opiate. How long before someone tries to invoke a BAKER ACT/5150 on some within the community? Isn’t filing a false police report ILLEGAL – please read below
I am sharing the following:
Pain Community: So I’m being investigated not APDF and Claudia was absolutely right. Brittney Dulworth, Kelli Sprague Baker, Claudia and apparently Beverly Diaz and Bev Shulman, which I’m surprised about. So here’s the deal, they sicked the agents on me for selling drugs because I gave tens of thousands of names to doctors who were good to pain patients in the past. They turned in a doctor in Indiana and I’m frustrated and worried about the gentleman. Someone who works for the pain community turning in doctors? Okay confused and confused to why she didn’t do the research. My phone contains an abundance of patients who reached out for help with names of medications and doctors names. Amanda and I obtained an attorney and plan to go to town on all these people. Doctors have left that organization and left messages on her wall as to why before Claudia turned off comments on the Doctor’s posts which led to the Doctor’s reaching out to me. What this does for patients now is the old generic google search, the eenie, meenie miney mo for Doctor’s. As soon as this is resolved which shouldn’t take too long, I will start my crusade again because to hell with them I’m here for the real deal, the patients in dire need of obtaining Doctors that can help CPP’s which is what I always stood for. That being said if any and I repeat ANY of you are on her list of groups, I’m so sorry I won’t be able to help you for obvious reasons and this pains me as she even posted she was the cause of the investigations. Y’all want an advocate like that then good luck my friends! I’m more than a little pissed as it cost me a small fortune to protect all the folks and doctors I’ve helped! Until this calms down APDF advocates will do the absolute best they can at finding you doctors! They may know a guy. But I will be staying quiet and invisible which is hard for me to do but I must for my family first and foremost as well and my APDF family. I’m so glad these women work so close to law enforcement and I wish you all well. Me personally I wouldn’t trust them to ride my bike. Its up to you though and as for now any groups that support her and her peoples bullying will not be working with APDF. I never cared what group you belonged to before but now I do because I have been put in a position where I have to. $5,000 in lawyer fees cuts a lot of ties and sadly it had to come down to that. These Doctors and PA’s that defended me are my heroes and the heroes of the CPP community as a whole. We will be back with a damn vengeance sooner rather than later and maybe Claudia and Company knows some more Doctors but hey good luck. In the meantime I will be working my ass off as usual in the background of course. and if you know anyone from APDF please reach out with any questions and concerns for your medical needs. If CM people can’t help then maybe APDF will find you a solution. Cancer spreads fast folks and that’s all I got to say. One thing for sure she does have access to law enforcement I can guarantee you that. Still off Social media besides Tik Tok and IG until she gets a hold of that. Call me crooked, call me a con man, call me anything you want maybe I am all that but one thing I always stood for is chronic pain patients. While my family is eating bologna and top ramen because of all the legal fees as the lawyer is eating snow crab and prime rib, know I will protect all of your information even if I have to go to prison. Signed, Some guy in Kentucky
A couple a years ago Barb had a “no efficacy ” with her C-II , when we had it fill at the Winn Dixie close to our FL condo. It was made by Rhodes – which at the time was owned by Purdue Pharma. I talked to the PIC at the pharmacy and she stated that was the ONLY BRAND that Winn Dixie allowed them to purchase from the wholesaler.
The pt that shared that the generic company that she got was Camberhttps://www.camberpharma.com/Its parent company, Hetero of Hyderabad India, this website https://www.drugs.com/manufacturer/camber-pharmaceuticals-inc-219.html had this statement “Camber Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 93 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.” does that last statement mean that the same meds, in the same bottle – just has a different label/name on the outside of the bottle ?
Some pt have asked me… if they could get the potency of their meds tested… of course they can, I understand such tests are $200 -$300 each time….however if the med is produced off shore … how are they going to sue someone in India or Pakistan ? The FDA is not going to do anything… if you complain to your insurance company – for paying for “defective meds”… they will just tell you to get a med from a different pharma.
It is ILLEGAL for a pharmacy to compound meds that are commercially available… but compounding a product that has been independently tested is not meeting the FDA requirement that a med must be between 95%-105% of what is stated on the label.
However, a compounding pharmacy and a doc could come to some sort of an agreement about a specific combination of meds to be compounded. Because compounding pharmacies are allowed to do anticipatory compounding and keep 7-14 days on hand and there are ways to basically do this in a semi-automated process… not how making compounded meds and putting them in capsules – BACK IN THE DAY.
Hydrocodone is not available in a 12.5 mg dose and there use to be a commercially available product that was Demerol and Phenergan… but it was finally figured out that long term use of Demerol created some toxic by products, but Phenergan/Promethazine is known to potentiate the effects of opiates… same thing could be done with Oxycodone … there is no 7.5 mg or 12.5 mg commercial dose.
Insurance companies don’t like to pay for compounding meds, but if the pt clinically showed BETTER PAIN MANAGEMENT with the compounded med than the generic they were taking… could give enough valid reasons for the insurance to pay for the compounded med. IMO, Medicare Part D & Medicare Part C… has a very well defined appeal process and following their rules on appeals, the vast majority of pts seeing a benefit out of a compounded med… perhaps at least 90% would end up getting their meds paid for..
The pt is going to have to start the discussion with their doc that has a lot of pain pts… here is a link to find a independent compounding pharmacy by zip code and radius https://ncpa.org/pharmacy-locator these “poor” generic meds may cause a pt to end up showing “NO OPIATES IN THEIR URINE” and could get kicked from the practice.
Maybe everyone is HAPPY… the doc because the pt is getting better pain management, so is the pt, the compounding pharmacy is happy getting more business… the pharmacy that has been dispensing the cheapest meds they can buy – loses business and so does the generic pharma
Hassles with prior authorization, delivery make it harder to dispense needed medications
Pharmacy benefit managers (PBMs) are requiring more and more patients to use specialty pharmacies to obtain their drugs — especially for cancer and other chronic illnesses — and medical specialty groups are saying that it’s increasing paperwork and hassle for themselves and their patients without adding any value.
Wayne Woodbury, RPh, pharmacy director at Southern Oncology Specialists in Huntersville, North Carolina, had one patient who regularly received an IV immunoglobulin (IVIG) infusion. “Every year, at the beginning of the plan year when she would renew, [the PBM] would say, ‘This medication you get, an IVIG, you can’t fill that through the provider’s pharmacy; you’ll have to use ours.'”
Patient Pushback Required
The first year that happened, “I pushed back as far as I could; I called the insurance carrier that the PBM owned and told them, ‘This is a therapy that is weight-based and it’s therapeutic-level-based,” Woodbury said in a phone interview. “Every month, the patient comes in, she gets blood work and gets weighed, and based on the lab work and her weight, the dose is determined, so our provider would prefer that we’d be able to dispense that and dose-adjust accordingly, rather than getting the shipment from the preferred pharmacy and [risking] underdosing or overdosing.'” Woodbury said he was told that although he couldn’t make that request, the patient herself could do it, and she was able to get an override for it after several hours on the phone, he said.
That worked for 2 years, but then the patient’s employer switched insurers and a new PBM was involved, Woodbury said. Not only that, but the PBM was using a third-party intermediary to manage the prescription component — “to deal with all of the prior authorizations, deal with the prescription claims coming in and where they were sent,” he continued. “I think they use them for a clearinghouse of sorts, getting the information and ascertaining what level of treatment is this and how can we best get this medication distributed?”
Woodbury’s office tried again to get an exception for this patient “and they were an outright ‘No,'” he said. “Unfortunately we weren’t able to provide the medication for the first time in 3 years … so we had it shipped to [an approved pharmacy] and they ship it to our office every month. If it’s not here in time, we may have to change her appointment.”
The intermediary gave the patient a list of reasons why they wouldn’t allow the in-house pharmacy dispensing, “a long list of what they called negligent acts by us, saying when they initially sent the request for the prescription, we didn’t send it back in a timely manner, didn’t get prior authorizations in a timely manner, and refused to give them clinical information,” Woodbury said, adding that none of that was true. “These are all things we do as part of our process — what it takes them 7 to 10 days to do, we can do in a matter of 2 hours to a day.”
Woodbury said he does see a role for PBMs “when it comes to maintenance therapies for certain disease states, because those are disease states where the therapy is established … You know what therapy you’re going to be on, and the monitoring is not as frequent as acute indications in the oncology/hematology space. There’s a place for them there; they are able to offer medication in bulk, sometimes at a discount.”
“To Us, It’s a Person”
Laurie Dieringer, MBA, office administrator at the Lafayette Cancer Center in Lafayette, Indiana, is having similar experiences at her office’s multispecialty infusion center. One patient in particular had been on a chemotherapy drug for a while, “and he’s been filling it in-office for the last couple of years,” Dieringer said. “I went to process the refill in July and got a rejection — all of a sudden we’re out of network and he has to get it at the specialty pharmacy. There was no [prior] notification to the office or the patient.”
This is further complicated by the fact that “a lot of these patients have copay assistance or foundation assistance,” which Dieringer helps manage. In addition, when there’s a dose reduction, “I know it instantly — I don’t have to wait and send a fax” to the outside pharmacy, which otherwise autofills the refill for the same dosage, she said.
Dieringer informed the patient of the change. He was upset and pointed out that he was still working, and asked, “‘Is it going to get mailed to my house? What if somebody steals it?’ That’s a valid concern,” she said. To the PBM, “it’s just a fill. To us it’s a person, it’s a patient and you must try and do the best for the patient.”
Eventually Dieringer’s office was able to convince the specialty pharmacy to ship the medication to another nearby pharmacy so the patient could pick it up there, she said, adding that sometimes prescriptions are delayed because the specialty pharmacy needs to contact the patient about something and the patient doesn’t recognize the phone number and doesn’t answer. “It can take weeks — and I’ve even had it take months — for the patient to get their medication.” The hassles of having to use the specialty pharmacy — a process called “white-bagging” — are so great that two local hospitals have refused to do it and are now sending all their infusion patients to the center Dieringer works at, she said.
Other Specialties Also Affected
And it’s not just oncologists that are having this problem, according to Madelaine Feldman, MD, president of the Coalition of State Rheumatology Organizations. Rheumatologists have been having the same issue with their infusion drugs, she said in a phone interview. “We’ve been fighting against white-bagging, which has been an issue, over the last 3 years or so.”
Although PBMs say that white-bagging can save money for employer groups, oftentimes that doesn’t seem to be the case, Feldman said, noting that one member of the coalition’s Payer Issue Response Team is the office manager for her husband’s rheumatology practice, and she has found that the price that her office would “buy and bill” for a particular drug is often cheaper than the price that she is quoted by PBM pharmacy technicians or what the human resources person in a self-insured employer’s office says they are getting billed for.
Asked to comment on the issue, the Pharmaceutical Care Management Association — an industry group for PBMs — said in a statement that “Specialty pharmacy dispensing on physician-administered drugs is often much less costly and allows for claims processing to occur in real time through the drug benefit rather than through the medical benefit, where physician ‘buy and bill’ can lead to payment delays and high costs. Specialty and other high-cost medications are often misused and underutilized without PBM and specialty pharmacy management programs, support systems, and monitoring tools in place.”
The association included a comment from a 2019 Massachusetts Health Policy Commission report, which found that “clinician-administered drugs are typically high-cost, and spending for clinician-administered drugs represented almost one-quarter of all commercial drug spending and 4% of total commercial health care spending in Massachusetts in 2015. Spending for these drugs is also growing rapidly; commercial spending for these drugs grew 5.1% in 2015 and 9.5% in 2016.” MedPage Today also sought comment from one of the nation’s largest PBMs, but they were unable to respond by press time.
About 17% of enrollees in Medicaid and the Children’s Health Insurance Program, or 15 million people, could lose their coverage when states resume regular eligibility checks once the COVID-19 public health emergency ends, HHS projected in a report from the Office of the Assistant Secretary for Planning and Evaluation.
Loss of eligibility will require 9.5% of beneficiaries to transition to another source of health insurance, while nearly 8% will leave the program despite remaining eligible due to difficulty navigating the renewal process and other administrative issues, HHS reported.
The agency said it is taking steps to reduce the risk of people becoming uninsured at the end of the public health emergency, including working with state and federal marketplaces to facilitate enrollment in other coverage options and stepping up outreach and education efforts. About 5.3 million children and 4.7 million young adults ages 18 to 34 are predicted to lose coverage. Of those, nearly a third are Latino and 15% are Black.
Dive Insight:
Health policy experts have been sounding the alarm about potential coverage losses for millions of Americans, including children, when pandemic protections expire. The nation’s uninsured rate fell to a historic low of 8% in the first quarter of this year, due in large part to the suspension of Medicaid coverage terminations that has swelled the number of participants in the program.
To help mitigate the disruption, the CMS issued guidance to assist states in November 2021 for transitioning those who will lose Medicaid and CHIP eligibility to other health insurance, such as subsidized plans, through Affordable Care Act marketplaces.
The extension of premium subsidies in the new Inflation Reduction Act is expected to improve access to alternative coverage for some losing Medicaid eligibility at the end of the public health emergency. The legislation extends enhanced marketplace subsidies until 2025.
Of those predicted to lose Medicaid and CHIP eligibility, 2.7 million people are expected to qualify for marketplace premium tax credits, the ASPE report said. Among this group, more than 60% are expected to qualify for zero-premium marketplace plans under the provisions of the American Rescue Plan. Another 5 million people are expected to obtain employer-sponsored insurance.
An estimated 383,000 people projected to lose Medicaid eligibility would fall in a coverage gap in the 12 non-expansion states because they have incomes too high for Medicaid but too low for marketplace tax credits.
Coverage losses due to administrative hurdles are also a high risk due to the volume of redeterminations that states must conduct and the length of time since Medicaid agencies last communicated with many beneficiaries, ASPE warned. The CMS is coordinating efforts with state Medicaid and CHIP agencies to minimize coverage lapses, the report added.
In this episode, I’ll discuss an article comparing IV acetaminophen with IV hydromorphone for acute pain in elderly ED patients.
“Episode 740: Two equally bad ways of treating acute pain in elderly ED patients?”The Elective Rotationpharmacyjoe.com | Critical Care | Hospital Pharmacy | PGY-1 Pharmacy Residency
The authors sought to compare the efficacy and adverse event profile of 1,000 mg of intravenous acetaminophen to that of 0.5 mg of intravenous hydromorphone among patients aged 65 years or more with acute pain of severity that was sufficient enough to warrant intravenous opioids.
The primary outcome being investigated was an improvement in a 0 to 10 pain score from baseline compared to 60 minutes after study medication was administered. The secondary outcomes included the need for additional analgesic medication and any adverse events that could be related to the study medication. The authors pre-specified a minimum clinically important difference of an improvement of 1.3 or more on the 0 to 10 pain scale.
The patients enrolled definitely represented a cohort with severe acute pain as the median baseline pain score was 10/10.
After 60 minutes, the patients who received 1000 mg IV acetaminophen improved by 3.6 and the patients who received 0.5 mg IV hydromorphone improved by 4.6 out of 10.
Overall pain relief after 1 dose however was not very good for either group. Almost half of the IV acetaminophen patients required additional doses of an analgesic, as did just over one-third of the patients who received IV hydromorphone.
Adverse events were similar between groups and minimal consisting of dizziness, drowsiness, headache, and nausea.
Unfortunately, it seems that efforts to provide analgesia with lower doses of opioids like 0.5 mg IV hydromorphone or alternatives to opioids like IV acetaminophen cannot reliably provide adequate pain relief in a cohort of elderly ED patients with severe acute pain.
To access my free download area with 20 different resources to help you in your practice, go to pharmacyjoe.com/free.
The Hippocratic Oath is not what you think it is. It was never intended to define the responsibilities of a physician. Rather, it was written by students of Hippocrates to distinguish their training from other physicians who were trained elsewhere.
Think of it like antiquity’s version of branding. It gave physicians practicing the Hippocratic method a competitive advantage in the clinical marketplace of patients.
Dr. Rudolf Virchow, the father of pathology, succinctly epitomizes the ethos of the report: “Medical practice is nothing but a minor offshoot of pathological physiology as developed in laboratories of animal experimentation.”
The report may have standardized medical education, but its more lasting consequence was to couple medicine with science, prioritizing the biomedical model over the experiential model of medicine.
History does not repeat itself, but it sure rhymes. While never overtly proven, many believe Flexner’s report was motivated by oil barren John D. Rockefeller, who sought to convert his large storage of petroleum into novel pharmaceuticals that could be used to treat diseases that had no cure a century ago.
But in order to treat, we have to first define treatment, which implies we need data and outcomes to study. As a result, we saw the growth of biomedical medicine, which determines a particular treatment by applying the scientific method into medicine.
We do not intend to belittle recent medical advancements made by the pharmaceutical industry. Indeed, the mRNA COVID vaccines are nothing short of a miracle. But we do see a conspicuous pattern where medicine is influenced by covert political pressures under the guise of either standardizing or improving medical care.
We see it repeating itself once again when we look at today’s post-pandemic healthcare.
It seems like all of healthcare is at the eye of the political storm. The repeal of Roe v. Wade has galvanized abortion into a voting issue. Opioid litigation continues to make headline news, right alongside escalating numbers of opioid overdoses and calls for harm reduction policies.
It seems all things healthcare are now all things political. Health disparities in patient outcomes are now acknowledged to correlate with systemic inequities in societies. Climate change is now a systemic health crisis, as per the American Medical Association.
These insights are undoubtedly important advancements in medicine. Few would argue otherwise. But we must be wary of the underlying motivations that drive them. They appear decidedly political.
Healthcare has always projected an idealistic front, but the underlying factors that influence its advancements have usually been political in nature – whether it was the students of Hippocrates seeking a competitive advantage or an industry-funded academic report.
We must not lose sight of this as we continue to mold a post-pandemic model of healthcare. It remains far too political to solely focus on patient care. It seems like healthcare is a branch of politics instead of an independent entity.
As it currently stands, to predict trends in healthcare, watch how the political winds blow. They carry the sails of healthcare. This is the problem.